Publications by authors named "John Shinn"
A practical guide to selecting and using new ulcerative colitis therapies.
Curr Opin Gastroenterol
July 2024
Article Synopsis
- New biologics and small molecule treatments for moderate-to-severe ulcerative colitis, including mirizikizumab and upadacitinib, have been approved, but there are no direct comparison studies available to guide their use.
- Clinical trials show mixed results: ozanimod, etrasimod, and mirizikizumab have lower remission rates in patients with prior biologic experience, while upadacitinib performs similarly; however, it carries the highest risk of adverse events.
- Experts suggest using ozanimod or etrasimod for mild-to-moderate cases and recommending mirizikizumab for moderate-to-severe cases, with a careful consideration of patient history when choosing between upad
Chronic airway disorders, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma, are associated with persistent pulmonary inflammation and goblet cell metaplasia and contribute to significant morbidity and mortality worldwide. While the molecular pathogenesis of these disorders is actively studied, little is known regarding the transcriptional control of goblet cell differentiation and mucus hyperproduction. Herein, we demonstrated that pulmonary allergen sensitization induces expression of FOXM1 transcription factor in airway epithelial and inflammatory cells.
View Article and Find Full Text PDF